Outcome of two pairs of monozygotic twins with pleuropulmonary blastoma: case report

• Main Authors: Shihan Zhang, Xisi Wang, Sihui Li, Siyu Cai, Tong Yu, Libing Fu, Na Zhang, Xiaoxia Peng, Qi Zeng, Xiaoli Ma
• Format: Article
• Language: English
• Published: BMC 2020-10-01
• Series: Italian Journal of Pediatrics
• Subjects: Monozygotic twins; Pleuropulmonary blastoma; Long-term survival
• Online Access: http://link.springer.com/article/10.1186/s13052-020-00912-6

Abstract Background Pleuropulmonary blastomas (PPB) are rare aggressive paediatric lung malignancies and are among the most common DICER1-related disorders: it is estimated that 75–80% of children with a PPB have the DICER1 mutation. DICER1 mutations are responsible for familial tumour susceptibility syndrome with an increased risk of tumours. In approximately 35% of families with children manifesting PPB, further malignancies may be observed. Symptoms of DICER1 syndrome may vary, even within monozygotic twins. Preventive screening of carriers with DICER1 mutations is important and follow-up is undertaken as recommended by the 2016 International PPB Register. Case presentation We present two pairs of monozygotic twins. In one pair of 4-year, 2-month old girls, both with DICER1 mutation, one developed PPB(II) and her identical sibling had acute transient hepatitis. In the other pair of 19-month-old female babies, one had a history of bronchopulmonary hypoplasia and developed PPB(III) without DICER1 mutation, and her identical sibling had allergic asthma. Both patients with PPB were treated with R0 resection and received 12 cycles of postoperative chemotherapy. At the most recent review, the twins had been followed up for six and eight years, respectively, and they all remained healthy. However, the height and weight of the patients with PPB were lower than those of their respective identical sister. Conclusions PPB is rare, especially in monozygotic twins. We emphasise the importance of genetic testing and follow-up in monozygotic twins with PPB. During the follow-up, children surviving PPB should be monitored closely for growth and development disorders which caused by chemotherapy.